The REMS Publication Paradox The Jamali/Lemery/Ayalew et al Article Reviewed

被引：0

作者：

Andrews, Elizabeth B. ^{[1
]}

Kaye, James A. ^{[1
]}

Van Bennekom, Carla ^{[2
]}

机构：

[1] RTI Int, RTI Hlth Solut, Res Triangle Pk, NC USA

[2] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA

来源：

ONCOLOGY-NEW YORK | 2009年 / 23卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：715 / 721

页数：3

共 20 条

[1]

*CDCP, GUID DEF PUBL HLTH R

[2]

*DEP HLTH HUM SERV, 2008, NEWS OHRP CONCL CAS

[3]

*DEP HLTH HUM SERV, 2002, 3 LETT BOST U MED CT

[4]

*DEP HLTH HUM SERV, OHRP QUAL IMPR ACT F

[5]

*DEP HLTH HUM SERV, 2007, 3 LETT J HOPK U SCH

[6] Phase I trial of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy [J].

Gordon, MS ;

McCaskillStevens, WJ ;

Battiato, LA ;

Loewy, J ;

Loesch, D ;

Breeden, E ;

Hoffman, R ;

Beach, KJ ;

Kuca, B ;

Kaye, J ;

Sledge, GW .

BLOOD, 1996, 87 (09) :3615-3624

[7]

GOSTIN LO, 2004, PUBLIC HLTH PRACTICE

[8] Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin [J].

Isaacs, C ;

Robert, NJ ;

Bailey, FA ;

Schuster, MW ;

Overmoyer, B ;

Graham, M ;

Cai, B ;

Beach, KJ ;

Loewy, JW ;

Kaye, JA .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (11) :3368-3377

[9]

Jamali F, 2009, ONCOLOGY-NY, V23, P704

[10] Practitioner acceptance of the dofetilide risk-management program [J].

LaPointe, NMA ;

Kramer, JM ;

Weinfurt, KP ;

Califf, RM .

PHARMACOTHERAPY, 2002, 22 (08) :1041-1046

← 1 2 →